Harrow Health, Inc. (HROW): Price and Financial Metrics


Harrow Health, Inc. (HROW): $9.55

-0.15 (-1.55%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

HROW POWR Grades


  • Quality is the dimension where HROW ranks best; there it ranks ahead of 89.55% of US stocks.
  • The strongest trend for HROW is in Value, which has been heading up over the past 52 weeks.
  • HROW's current lowest rank is in the Growth metric (where it is better than 33.59% of US stocks).

HROW Stock Summary

  • With a year-over-year growth in debt of 215.25%, Harrow Health Inc's debt growth rate surpasses 95.66% of about US stocks.
  • Over the past twelve months, HROW has reported earnings growth of -153.41%, putting it ahead of just 13.75% of US stocks in our set.
  • Harrow Health Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -20.56%, greater than the shareholder yield of merely 13.47% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Harrow Health Inc, a group of peers worth examining would be CDXC, HAYN, SREV, NAOV, and KRKR.
  • Visit HROW's SEC page to see the company's official filings. To visit the company's web site, go to www.harrowinc.com.

HROW Valuation Summary

  • HROW's price/earnings ratio is 40.4; this is 10.68% higher than that of the median Healthcare stock.
  • HROW's price/sales ratio has moved NA NA over the prior 151 months.
  • HROW's price/earnings ratio has moved up 43.4 over the prior 151 months.

Below are key valuation metrics over time for HROW.

Stock Date P/S P/B P/E EV/EBIT
HROW 2021-08-31 4.6 12.3 40.4 27.4
HROW 2021-08-30 4.3 11.5 37.8 25.7
HROW 2021-08-27 4.1 10.9 36.0 24.4
HROW 2021-08-26 4.0 10.8 35.6 24.2
HROW 2021-08-25 4.1 11.0 36.1 24.5
HROW 2021-08-24 4.1 11.1 36.4 24.7

HROW Growth Metrics

  • The 3 year price growth rate now stands at 25.47%.
  • Its 3 year revenue growth rate is now at 257.4%.
  • Its 2 year cash and equivalents growth rate is now at 42.6%.
HROW's revenue has moved up $21,199,000 over the prior 30 months.

The table below shows HROW's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 62.571 10.749 7.054
2021-03-31 52.497 2.658 9.767
2020-12-31 48.871 -1.1 -3.357
2020-09-30 46.88 1.118 -1.849
2020-06-30 45.236 -1.619 -21.956
2020-03-31 50.692 1.876 -24.097

HROW's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HROW has a Quality Grade of B, ranking ahead of 89.56% of graded US stocks.
  • HROW's asset turnover comes in at 0.893 -- ranking 27th of 681 Pharmaceutical Products stocks.
  • CGEN, ACOR, and CALA are the stocks whose asset turnover ratios are most correlated with HROW.

The table below shows HROW's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.893 0.747 0.148
2021-03-31 0.943 0.722 0.201
2020-12-31 0.917 0.704 -0.020
2020-09-30 0.873 0.699 0.005
2020-06-30 0.861 0.680 -0.359
2020-03-31 0.898 0.675 -0.374

HROW Price Target

For more insight on analysts targets of HROW, see our HROW price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.13 Average Broker Recommendation 1.38 (Strong Buy)

HROW Stock Price Chart Interactive Chart >

Price chart for HROW

HROW Price/Volume Stats

Current price $9.55 52-week high $11.24
Prev. close $9.70 52-week low $4.65
Day low $9.45 Volume 63,400
Day high $9.73 Avg. volume 222,031
50-day MA $9.67 Dividend yield N/A
200-day MA $8.74 Market Cap 256.84M

Harrow Health, Inc. (HROW) Company Bio


Harrow Health, Inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the United States. The company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. It also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. Its products portfolio includes topical eye drop drug candidates, including SURF-100 and SURF-200; SURF-300, an oral capsule for treating patients suffering from ocular surface diseases, and DED signs and symptoms; Klarity drops to protect and rehabilitate the ocular surface pathology for patients with DED; MELT-100, a drug that is administered sublingually for conscious sedation during cataract surgery; MAY-66 that is used for the treatment of symptoms associated with Peyronie's disease; MAY-44, a non-estrogen topical analgesic gel; and other drug candidates for rare diseases. In addition, the company engages in the development of MAY-88, an oral anhydrous extend release suspension of pentosan polysulfate sodium for interstitial cystitis. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.


HROW Latest News Stream


Event/Time News Detail
Loading, please wait...

HROW Latest Social Stream


Loading social stream, please wait...

View Full HROW Social Stream

Latest HROW News From Around the Web

Below are the latest news stories about Harrow Health Inc that investors may wish to consider to help them evaluate HROW as an investment opportunity.

Harrow Health to Announce Third Quarter 2021 Financial Results on November 9, 2021

NASHVILLE, Tenn., October 25, 2021--Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic‑focused healthcare company, today announced that it will release its financial results for the third quarter and nine months ended September 30, 2021, on Tuesday, November 9, 2021, after the market close. The Company will also post its third quarter Letter to Stockholders to the "Investors" section of its website, harrowinc.com. Harrow Health will host a conference call and live webcast at 4:45 p.m. Eastern Tim

Yahoo | October 25, 2021

Jump Financial LLC Boosts Stock Position in Harrow Health, Inc. (NASDAQ:HROW)

Jump Financial LLC boosted its holdings in Harrow Health, Inc. (NASDAQ:HROW) by 69.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 21,500 shares of the company’s stock after acquiring an additional 8,800 shares during the period. Jump Financial LLC’s holdings in Harrow Health were worth […]

Dakota Financial News | October 22, 2021

Harrow Health, Inc. (NASDAQ:HROW) Shares Purchased by Jump Financial LLC

Jump Financial LLC boosted its holdings in Harrow Health, Inc. (NASDAQ:HROW) by 69.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 21,500 shares of the company’s stock after acquiring an additional 8,800 shares during the period. Jump Financial LLC’s holdings in Harrow Health were worth […]

Dakota Financial News | October 22, 2021

Here's What Harrow Health, Inc.'s (NASDAQ:HROW) Shareholder Ownership Structure Looks Like

If you want to know who really controls Harrow Health, Inc. ( NASDAQ:HROW ), then you'll have to look at the makeup of...

Yahoo | September 27, 2021

Harrow Health Provides $13.5 Million Senior Secured Loan to Melt Pharmaceuticals

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, and Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first-in-class medicines for sedation and analgesia, today announced that Harrow Health has provided a $13.5 million senior secured loan to Melt Pharmaceuticals. Melt Pharmaceuticals plans to use the proceeds to conduct its pivotal Phase 2 efficacy study for the companys lead drug candidate, MELT-300,

Business Wire | September 2, 2021

Read More 'HROW' Stories Here

HROW Price Returns

1-mo 2.80%
3-mo 7.06%
6-mo 24.51%
1-year 94.50%
3-year 136.39%
5-year 223.73%
YTD 39.21%
2020 -11.83%
2019 36.73%
2018 234.71%
2017 -32.00%
2016 -63.92%

Continue Researching HROW

Here are a few links from around the web to help you further your research on Harrow Health Inc's stock as an investment opportunity:

Harrow Health Inc (HROW) Stock Price | Nasdaq
Harrow Health Inc (HROW) Stock Quote, History and News - Yahoo Finance
Harrow Health Inc (HROW) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8434 seconds.